Abstract: The invention herein provides for an oral pharmaceutical composition adapted for use in capsular dosage forms comprising acetaminophen and a lactate salt alone or in combination with an acetate salt. Compositions of the invention exhibit improved solubility characteristics of the active ingredient per given fill volume, thereby permitting the use of smaller capsule sizes to deliver a given effective dose of the active ingredient. Compositions of the invention also exhibit improved clarity per concentration of active ingredient. The invention also provides for a capsular dosage form containing the composition.
Abstract: A percutaneously absorptive preparation is provided, which preparation having a support and an adhesive layer having a release-controlling layer, which is formed at least on one side of the support, wherein the adhesive layer contains an adhesive and 0.5–60 wt % of a drug except 1,2-ethanediol derivatives.
Type:
Grant
Filed:
September 5, 2001
Date of Patent:
April 18, 2006
Assignee:
Nitto Denko Corporation
Inventors:
Mitsuhiko Hori, Kensuke Matsuoka, Kenjiro Minomi, Yoshihisa Nakano
Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.
Abstract: The present invention relates to compositions and methods for removing an epidermal portion of the skin of a patient by microdermabrasion with a crystalline emulsion. The crystalline emulsion includes a mixture of coated crystals and a carrier. The coated crystals are formed by combining magnesium oxide, aluminum oxide or a combination of the two with methicone, adding a catalyst, such as ammonia, and mixing, then baking the resulting slurry mixture until the mixture is dry. The coated crystals are able to stay in the emulsion in a carrier.
Abstract: A hair care formulation is disclosed that enhances visual and/or tactile qualities of the hair. Embodiments of the formulation include a pyridoxine hydrochloride (vitamin B6), a glycyrrhizinic acid, a pantothenic acid, a pyrrolidone, an antimicrobial agent, zinc, and an antioxidant. The formulation may be included in separate hair care products, such as a shampoo, conditioner and scalp serum. In a particular embodiment, the formulation is included in a daily shampoo, a deep cleansing shampoo, a daily conditioner, a deep conditioner, and a scalp serum. In some of these examples, each of the hair care products contain at least 10 vitamins, minerals, and herbs, such as swertia extract, ginseng extract, saw palmetto extract, pyridoxine hydrochloride (vitamin B6), zinc pyrrolidone carboxylic acid, superoxide dismutase, dipotassium glycyrrhizate, green tea extract, and tea tree oil.
Type:
Grant
Filed:
July 31, 2003
Date of Patent:
April 11, 2006
Assignee:
Shaklee Corporation
Inventors:
Mukhtar Siddiqui, Yoshiaki Kawasaki, Arshad H. Malik, Rita W. Ayer
Abstract: The present invention is directed to microdispersions and pharmaceutical compositions containing a synthetic, bioabsorbable, biocompatible liquid polymer that is the reaction product of a polybasic acid or derivative thereof, a polyol and a fatty acid, the liquid polymer having a melting point less than about 40° C., as determined by differential scanning calorimetry, and a synthetic, bioabsorbable, biocompatible polymeric wax comprising the reaction product of a polybasic acid or derivative thereof, a fatty acid and a polyol, the polymeric wax having a melting point less than about 70° C., as determined by differential scanning calorimetry.
Type:
Grant
Filed:
June 25, 2002
Date of Patent:
April 11, 2006
Inventors:
Aruna Nathan, Joel Rosenblatt, Steven C. Arnold
Abstract: The invention relates to pharmaceutical formulations for use in the administration of lipophilic medicaments via mucosal surfaces. In particular the invention provides pharmaceutical formulations for use in administration of a lipophilic medicament via a mucosal surface which upon hydration form an emulsion containing the lipophilic medicament which is capable of adhering to a mucosal surface and allowing controlled release of the medicament. The invention further provides pharmaceutical formulations which contain, as active ingredients, specific combinations of cannabinoids in pre-defined ratios.
Abstract: Physiologically acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer such as pullulan. Edible films are disclosed that include pullulan and antimicrobially effective amounts of the essential oils thymol, methyl salicylate, eucalyptol and menthol. The edible films are effective at killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath. The film can also contain pharmaceutically active agents. Methods for producing the films are also disclosed.
Type:
Grant
Filed:
April 18, 2001
Date of Patent:
April 11, 2006
Assignee:
Warner-Lambert Company LLC
Inventors:
Sau-Hung Spence Leung, Robert S. Leone, Lori D. Kumar, Neema Kulkarni, Albert F. Sorg
Abstract: The present invention addresses the problem of excessive discoloration in hydroquinone compositions of a neutral pH. Antioxidants in the hydroquinone phase and inorganic or amino acyl cationic salts of acidic ascorbyl esters, preferably sodium metabisulfite and magnesium ascorbyl phosphate respectively, are effective in stabilizing such hydroquinone compositions, which are used in treatment of pigmentation disorders. Protected retinoid may be added to these compositions for additional skin benefit effects.
Type:
Grant
Filed:
July 10, 2003
Date of Patent:
April 11, 2006
Assignee:
Medicis Pharmaceutical Corporation
Inventors:
Mitchell Wortzman, Philip J. Gordon, Eugene H. Gans, Bhiku G. Patel
Abstract: The present invention is for compositions and methods for managing the body weight of a subject using said compositions. Weight management, particularly weight gain and loss, is effectuated by producing a sensation of satiety in said subjects. The method of managing body weight includes administering the composition prior to food consumption, concurrent with food consumption, as replacement for food consumption and combinations thereof.
Type:
Grant
Filed:
June 26, 2000
Date of Patent:
April 11, 2006
Assignee:
The Procter & Gamble Company
Inventors:
Ronald James Jandacek, Gary Robert Kelm, Satinder Singh Bharaj, Jorge Villanueva Penafiel
Abstract: A shred resistant, ultra-high molecular weight polyethylene, micromesh interproximal device produced by fibrillating and slitting stretched polyethylene film having a tensile-strength from between about 0.7 GPa and about 5 GPa, where said polyethylene has an intrinsic viscosity of from between about 5 and about 50 dl/g and wherein said resultant micromesh tape is coated with an oral care substance at from between about 10 and about 120 mg/yd.
Abstract: There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing a controlled release drug capable of decreasing the post prandial blood glucose level close to the normal level with an immediate release drug. It is particularly preferable that the drug capable of decreasing the post prandial blood glucose level close to the normal level is nateglinide.
Abstract: Non-absorbent articles are disclosed. The non-absorbent articles include an effective amount of an aromatic inhibitory compound to substantially inhibit the production of exotoxins by Gram positive bacteria. The aromatic inhibitory compounds of the present invention have the general formula: wherein R1 is selected from the group consisting of H, —OR5, —R6C(O)H, —R6OH, —R6COOH, —OR6OH, —OR6COOH, —C(O)NH2, and NH2 and salts thereof; R5 is a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety; R6 is a divalent saturated or unsaturated aliphatic hydrocarbyl moiety; R7 is a trivalent saturated or unsaturated aliphatic hydrocarbyl moiety; R8 is a monovalent substituted or unsubstituted saturated or unsaturated aliphatic hydrocarbyl moiety which may or may not be interrupted with hetero atoms; R2, R3, and R4 are independently selected from the group consisting of H, OH, COOH, and —C(O)R9; R9 is hydrogen or a monovalent saturated or unsaturated aliphatic hydrocarbyl moiety.
Abstract: Disclosed are methods for treating urinary incontinence in a mammal wherein a composition comprising a biocompatible polymer, a biocompatible solvent, and a contrast agent is delivered to the periurethral tissue of the mammal.
Abstract: Oral solid pharmaceutical compositions with pH-dependent multiphasic release, containing, as active ingredient, a molecule useful in the inflammatory bowel disease therapy, are described, being such compositions suitable to the release of the active ingredient in the intestinal tract.
Abstract: A suppository of retaining in a lower region of rectum, which contains a suppository base containing: (A) a fatty acid triglyceride, (B) one or more C14-18 fatty acid glycerides, and (C) a base ingredient for retaining the suppository in the lower region of rectum, has quite high safety, does not melt by the body temperature when it is held by the fingers before insertion into the rectum so that it is easy to handle, does not deform by elevation of temperature during storage, and prevents stimulation to the rectum mucosa such as congestive hemorrhage and expansion of the rectum mucosa after the insertion.
Abstract: Methods for the simple, reliable application and local controlled release of selected anti-arrhythmia drugs from a hydrogel applied to or polymerized on the tissues of the heart or its vessels, especially in conjunction with cardiac bypass or other cardiac surgery, have been developed. The anti-arrhythmia drugs are incorporated into hydrogels that biodegrade and adhere to the tissues to which the anti-arrhythmic drugs are to be delivered. The hydrogels may be formed in vitro or in vivo. In a preferred embodiment, the drugs are effective to lengthen atrial effective refractory period. A particularly preferred drug is amiodarone.
Type:
Grant
Filed:
December 27, 2001
Date of Patent:
April 4, 2006
Assignee:
Genzyme Corporation
Inventors:
C. Michael Philbrook, James W. Burns, Kevin C. Skinner, Robert J. Miller
Abstract: There are provided lubricious ophthalmic solutions having a pH of between about 7.0 and about 8.0, consisting essentially of an aqueous solution of from about 0.5–4% by weight of a monographed polyol, borate calculated as the borate equivalent of 20–100% by weight of boric acid relative to said polyol, from about 0.1 to about 1.00% by weight of monographed polysorbate, a monographed preservative and a buffer. Suitably the polyol is polyvinyl alcohol In addition to polyvinyl alcohol (hereinafter PVA) the solution may include other monographed polymers as well as monographed pharmacologically active substances.
Abstract: The present invention provides a simple and improved multi-layered osmotic device (1) that is capable of delivering a first active agent in an outer lamina (2) to one environment of use and a second active agent in the core (5) to another environment of use. Particular embodiments of the invention provide osmotic devices in which the first and second active agents are similar or dissimilar. An erodible polymer coat (3) between an internal semipermeable membrane (4) and a second active agent-containing external coat (2) comprises poly(vinylpyrrolidone)-(vinyl acetate) copolymer. This particular erodible polymer results in an improved multi-layered osmotic device possessing advantages over related devices known in the art. The active agent in the core (5) is delivered through a pore (6) containing an erodible plug (7). The osmotic device (1) can be coated by a final finish coat (8).